Biotech company AVM Biotechnology LLC reported on Wednesday the receipt of approval from the US FDA to begin the clinical trials to evaluate its AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients.
This is the company's second safe to proceed clinical trial approval from the FDA within the past six months and the second study consists of two different ARDS patient populations: COVID-19-mediated moderate to severe ARDS and the with Influenza-mediated severe ARDS.
The company said that AVM0703 is a novel and proprietary formulation of high concentration of dexamethasone. The acute high or suprapharmacologic dose of AVM0703 mobilizes highly active Natural Killer T- (NKT) and cytotoxic T- cells and dendritic cells.
Within six hours of a single administration, AVM0703 kick-starts additional NKT cell activation, which is directly relevant to COVID-19- and Influenza-mediated ARDS because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected.
In conjunction, the rapid elimination of infected monocytes in COVID-19 patients could reduce ICU stays and decrease long-term lung damage. NKT mobilization could also provide long-term T-cell immunity, concluded the company.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma